LIQUIDIA CORPORATION Cash and Cash Equivalents
LIQUIDIA CORPORATION (LQDA) had Cash and Cash Equivalents of $284.18 million as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Balance Sheet › Assets › Assets, Current
us-gaap:CashAndCashEquivalentsAtCarryingValue · last filed 2026-08-12
- 2026-06-30: Cash and Cash Equivalents, at Carrying Value $284.18M.
- 2026-03-31: Cash and Cash Equivalents, at Carrying Value $222.79M.
- 2025-12-31: Cash and Cash Equivalents, at Carrying Value $190.68M.
- 2025-09-30: Cash and Cash Equivalents, at Carrying Value $157.50M.
| Period end | Cash and Cash Equivalents, at Carrying Value | Cash and Cash Equivalents, at Carrying Value as first filed |
|---|---|---|
| 2026-06-30 | $284.18M 10-Q · filed 2026-08-12 | |
| 2026-03-31 | $222.79M 10-Q · filed 2026-05-11 | |
| 2025-12-31 | $190.68M 10-Q · filed 2026-08-12 | |
| 2025-09-30 | $157.50M 10-Q · filed 2025-11-03 | |
| 2025-06-30 | $173.42M 10-Q · filed 2025-08-12 | |
| 2025-03-31 | $169.76M 10-Q · filed 2025-05-08 | |
| 2024-12-31 | $176.48M 10-K · filed 2026-03-05 | |
| 2024-09-30 | $204.37M 10-Q · filed 2024-11-13 | |
| 2024-06-30 | $133.09M 10-Q · filed 2024-08-07 | |
| 2024-03-31 | $157.86M 10-Q · filed 2024-05-13 | |
| 2023-12-31 | $83.68M 8-K · filed 2025-05-08 | |
| 2023-09-30 | $76.22M 10-Q · filed 2023-11-07 | |
| 2023-06-30 | $88.20M 10-Q · filed 2023-08-10 | |
| 2023-03-31 | $94.41M 10-Q · filed 2023-05-08 | |
| 2022-12-31 | $93.28M 10-K · filed 2024-03-13 | |
| 2022-09-30 | $98.32M 10-Q · filed 2022-11-08 | |
| 2022-06-30 | $103.84M 10-Q · filed 2022-08-11 | |
| 2022-03-31 | $57.79M 10-Q · filed 2022-05-12 | |
| 2021-12-31 | $57.49M 10-K · filed 2023-03-20 | $57.49M 10-K · filed 2022-03-17 |
| 2021-09-30 | $64.05M 10-Q · filed 2021-11-03 | |
| 2021-06-30 | $67.89M 10-Q · filed 2021-08-10 | |
| 2021-03-31 | $53.64M 10-Q · filed 2021-05-13 | |
| 2020-12-31 | $65.32M 10-K · filed 2022-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |